36 results about "CDC42" patented technology

The invention provides human polymorphisms that are associated with coronary artery disease (CAD). Polymorphisms in genes were identified that confer an increased susceptibility to CAD or a decreased susceptibility. Particular alleles of the polymorphisms were identified as being associated with differential risk. In particular an allele of CDC42 in combination with an allele of PARD3 was shown to confer increased risk of CAD.

Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and / or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more additional agents. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve specific inhibition of the Cdc42 GTPase to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject.

Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.

The present invention relates to the competence of oocytes for uterine implantation and development into living individuals. The invention more particularly relates to markers that are detected and measured in granulosa cells collected along with the oocytes during oocyte aspiration as it is done in assisted reproduction techniques. Markers include cytochrome P450 aromatase (CYP19A1), cell division cycle 42 (CDC42), 3-β-hydroxysteroid dehydrogenase 1 (3βHSD1), serpm peptidase inhibitor clade E member 2 (SERPINE 2), and adrenodoxm (ADX) that are detected and measured, using RT-PCR.

Compounds, compositions, and methods for specific inhibition of activated cdc42-associated kinase 1 (Ack1) are provided.

Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.

The invention relates to a nutritive composition which consists of resveratrol and yeast glucan and has the function of health protection. The nutritive composition overcomes the defects of poor treatment effect and toxic and side effects by adopting Western medicines for hyperglycemic and hypolipemic treatment in the prior art. The resveratrol is an important plant antitoxin and has the functions of antioxidation, prevention and treatment of cardiovascular diseases, prevention of cancer, antivirus and immunoloregulation; the yeast glucan has the functions of clearing intestine, regulating the blood sugar, reducing cholesterin, improving the immunity and so on; and when the two types of immunomodulator, namely the resveratrol and the yeast glucan, are combined and applied, Cdc42 expression is obviously improved, and the resveratrol and the yeast glucan have stronger synergism. For example, the resveratrol and the yeast glucan express obvious synergistic effect in monocytes and neutrophilic granulocytes, and three cytokines (IL-1, IL-6 and TNF-alpha) are obviously lifted; and the nutritive composition influences the restoring activity of spleen cells and fluorouracil-induced leucocytopenia.

The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type 1), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp, infections, especially including Entamoeba histolytica.

The present invention relates to compositions and methods useful in studying or modulating melanin pigmentation in the skin. Particularly, the invention relates to compositions comprising a substance capable of modulating the activity or expression of ALK6 (SEQ ID 2) or Cdc42 which in turn are capable of modulation of the transfer of melanin from melanocytes to keratinocytes and potentially from keratinocytes to keratinocytes. The invention also relates to assays for identifying such compositions, and methods of modulating skin pigmentation.

Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.

The present invention relates to improvement of epithelial or endothelial barrier function by increasing a level of myotonic dystrophy kinase-related Cdc42-binding kinases a (MRCKalpha) in one or more cells in the barrier.

The invention relates to a method for the treatment of cancer by changing the intracellular activity of cdc42. The activity can be increased by treatment with small molecules, for instance, treatment with non-hydrolyzable GTP-analogues of cdc-42. Also, the activity can be increased by inhibiting nm23-H1 and / or nm23-H2, which are factors having an inhibitory effect on the expression and / or activity of cdc-42. It is also shown that a decrease in the intracellular activity of cdc-42 has a beneficial effect. Further embodiments of the invention are the compounds for use in such methods, pharmaceutical preparations comprising such compounds and use of such compounds for the preparation of a medicament for treatment of cancer.

Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.

The invention relates to a compound in a structure disclosed as Formula I, which can be used for preparing a Cdc42 inhibitor. Morphological analysis on filopodia, Western blot Cdc42 phosphorylation and downstream effector protein WASP analysis, cell wound healing test and formation test indicate that the compound provided by the invention can inhibit all processes into which Cdc42 participates, and effectively inhibit the action of Cdc42. The compound provided by the invention effectively inhibits cell functions into which actin participates, such as dictyosome tissue and cell movement.

The invention discloses an application of a gene knockout animal as a skin barrier function disorder animal model. A skin keratinocyte Cdc42 gene knockout mouse is formed, the skin barrier function of the mouse is found to be obviously destroyed, and in the expression spectrum level of the gene, similar to clinical skin barrier function destruction type diseases such as specific atopic dermatitis (AD) and the like, the skin keratinocyte Cdc42 gene knockout mouse can be used as the animal model of the skin barrier function destruction type disease for foundation and clinical experiment research.

Compounds, compositions, and methods for specific inhibition of activated cdc42-associated kinase 1 (Ack1) are provided.

The present invention relates to a cell for producing a secreted protein comprising a polynucleotide comprising a nucleic acid sequence encoding a fast cycling cdc42 mutant and a polynucleotide comprising a nucleic acid sequence encoding a secreted protein. It also relates to a method for producing said cell and to a method for producing a secreted protein using said cell.

Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using compounds that inhibit p21 protein (Cdc42 / Rac)-activated kinase (PAK1).

The invention provides a method of inducing neurofibromatosis type 2 (NF2) in Schwann cells. The method comprises contacting the cells with laminin-1 so as to bind α6β1 integrin sufficiently to activate endogenous kinase Cdc42-Pak; and phosphorylating Schwannomin-S518 in the cells by the activated kinase, effectively inactivating. Schwannomin's tumor suppressor activity and allowing proliferation of subconfluent Schwann cells, thereby modeling NF2. The invention also includes a method of preventing a Schwann cell from forming a tumor by contacting the cell with an amount of tyrphostin AG825 sufficient to inhibit a receptor selected from ErB2, ErB3, β1 integrins and combinations thereof, so as to prevent phosphorylation of Schwannomin-S815 by one or more endogenous kinases.

The invention belongs to the technical field of screening of porcine molecular markers, and in particular relates to cloning and application of a CDC42 gene molecular marker related to porcine reproductive traits. The molecular marker is related to porcine reproductive traits such as litter size and birth weight traits. The molecular marker is cloned from a gene CDC42 which affects the developmentof the placenta and the embryo; the nucleotide sequence of the molecular marker is shown in SEQ ID NO. 1; a C / T allele mutation exists at 151bp of the sequence and causes Hpy188III-RFLP polymorphism.The invention also discloses the application of the molecular marker in correlation analysis of the porcine reproductive traits.

Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using compounds that inhibit p21 protein (Cdc42 / Rac)-activated kinase (PAK1).

The invention provides an evaluation gene group for prognosis prediction of gastric cancer and a corresponding kit. The evaluation gene group is obtained by screening genes comprised in a RhoA proteinactivity regulation pathway for regulating RhoA protein activity, wherein, the evaluation gene group comprises the following genes: RHOA, ARHGAP32, ARHGAP4, ARHGAP6, ARHGAP9, ARHGEF17, ARHGEF2, ARHGEF3, BCR, CDC42, CDKN1B, DLEC1, FARP1, NET1, NGEF, OBSCN, PRPF38B, SLC6A5, TSPAN1, VAV2, and VAV3.

The invention provides an evaluation gene group for prognosis prediction of gastric cancer and a corresponding kit. The evaluation gene group is obtained by screening genes comprised in a RhoA proteinactivity regulation pathway for regulating RhoA protein activity, wherein, the evaluation gene group comprises the following genes: RHOA, ARHGAP32, ARHGAP4, ARHGAP6, ARHGAP9, ARHGEF17, ARHGEF2, ARHGEF3, BCR, CDC42, CDKN1B, DLEC1, FARP1, NET1, NGEF, OBSCN, PRPF38B, SLC6A5, TSPAN1, VAV2, and VAV3.

The present invention relates to a cell for producing a secreted protein comprising a polynucleotide comprising a nucleic acid sequence encoding a fast cycling cdc42 mutant and a polynucleotide comprising a nucleic acid sequence encoding a secreted protein. It also relates to a method for producing said cell and to a method for producing a secreted protein using said cell.

The invention discloses an HLA-A2 restrictive bladder cancer tumor new antigen peptide sequence. The sequence is selected from any one or a combination of more of antigen sequences of the following 12genes: CDKN1A gene, RHOB gene, CDC42 gene, DDB1 gene, AHNAK gene, ANP32A gene, ALDH16A1 gene, MET gene, PRDX6 gene, MKI67 gene, GAK gene and DSG3 gene, and the antigen sequences are respectively shown as SEQ ID NO: 1-12. In addition, the invention discloses application of the antigen sequences in preparation of a bladder cancer diagnostic reagent and a bladder cancer therapeutic drug.

The invention provides a miRNA simulant and application thereof, and belongs to the technical field of regenerative medicine. The miRNA simulant is a miRNA 24-3p simulant, and the nucleotide sequence of the miRNA simulant is as shown in SEQ ID NO: 1. The miRNA simulant promotes corneal epithelial cell migration by up-regulating expression of cell migration related genes (CDC42, FRS2, CTGF, EGFR and MMP9), further accelerates healing of epithelial wounds, is a good medicine suitable for corneal epithelial defect repair, and provides a new direction for clinical medicine transformation.

The invention discloses a method for screening compounds with the ability of immune regulating through SAP-PIX-Cdc42 path. The invention also discloses the application of SAP-PIX-Cdc42 path modifier in the preparation of immune regulation drug. The invention confirms the SAP-PIX-Cdc42 path in cell for the first time; thus immunity can be promoted through adjusting the path.